Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Recruiting now

Conditions studied: Large B-Cell Lymphoma

In brief

This is a single-center real-world study aiming to explore predictive factors for the efficacy of CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Key facts

Study ID

NCT07236203

Run by

Fudan University

People needed

80

Starts

2024-02-29

Expected to finish

2027-08-30

Last updated by the study team

2025-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathological diagnosis confirmed as large B-cell lymphoma
• Patients with relapsed or refractory large B-cell lymphoma (R/R DLBCL) after receiving second-line or above systemic treatment
• Intend to use CAR-T products approved by NMPA for the treatment of R/R LBCL.
• Understand and voluntarily sign a written informed consent form. For patients without full civil capacity, their guardians must be informed and sign the corresponding informed consent form and note the date, as for the patient himself, informed consent may be obtained based on the specific circumstances.

You may not qualify if…

• Poor patient compliance
• During pregnancy or lactation
• After judgment by the researcher, the patient has other unsuitable conditions for inclusion in the study.

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.